Jiangsu Cowin Biotech Co Ltd
688426
Company Profile
Business description
Jiangsu Cowin Biotech Co Ltd is a national high-tech enterprise with independent intellectual property rights based in the field of life sciences. It provides innovative biological products and services to in vitro diagnostic users. The product line mainly includes molecular diagnostic raw materials enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents and others.
Contact
No. 1 Yaocheng Avenue
4th Floor, TQB Building
Jiangsu Province
Taizhou225300
CHNT: +86 52386201353
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
769
Stocks News & Analysis
stocks
ASX biotech expands diagnostics portfolio after FDA approval
FDA nod adds another growth driver for ASX share.
stocks
Is it time to bail on Australian stocks?
Is your home bias costing your portfolio better returns?
stocks
ASX share undervalued despite margin woes
Short term margin pressure yet shares remain undervalued on improved outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.50 | 25.20 | 0.28% |
| CAC 40 | 8,130.37 | 40.09 | 0.50% |
| DAX 40 | 25,516.33 | 114.05 | 0.45% |
| Dow JONES (US) | 52,005.60 | 87.51 | -0.17% |
| FTSE 100 | 10,701.14 | 43.01 | 0.40% |
| HKSE | 24,713.78 | 46.54 | 0.19% |
| NASDAQ | 26,166.69 | 185.12 | 0.71% |
| Nikkei 225 | 63,923.00 | 438.90 | 0.69% |
| NZX 50 Index | 13,622.72 | 138.50 | 1.03% |
| S&P 500 | 7,613.22 | 27.49 | 0.36% |
| S&P/ASX 200 | 8,696.50 | 24.00 | 0.28% |
| SSE Composite Index | 3,891.60 | 27.32 | 0.71% |